U.S. MarketsSeptember 24 at 07:02 AM

Acadia Pharmaceuticals (ACAD) said remlifanserin narrowly missed the primary endpoint of SAPS H+D with significance on the key secondary endpoint of CGI-S-ADP.

StockNow breaking-news AI analysis

Acadia Pharmaceuticals reported that remlifanserin narrowly missed the primary endpoint of SAPS H+D, but achieved significance on the key secondary endpoint of CGI-S-ADP.

1 stocks

ACADAcadia Pharmaceuticals Inc.$24.45Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Acadia Pharmaceuticals (ACAD) said remlifanserin narrowly missed the primary endpoint of SAPS H+D with significance on the key secondary endpoint of CGI-S-ADP.

What do investors think?

Today's market highlights

Oracle (ORCL) sends force majeure notice over New Mexico data centre; trying to put off payments on project if it's delayed

An Israeli source says "we do not see a real chance of reaching an agreement between the United States and Iran", Al Hadath reports

Iranian Security Council Secretary Rezaei says a new escalation from the US could open a 2nd front alongside the Strait of Hormuz, in Bab El-Mandeb

Acadia Pharmaceuticals (ACAD) said remlifanserin narrowly missed the primary endpoint of SAPS H+D with significance on the key secondary endpoint of CGI-S-ADP.

Related stocks

What do investors think?

Today's market highlights

Oracle (ORCL) sends force majeure notice over New Mexico data centre; trying to put off payments on project if it's delayed

An Israeli source says "we do not see a real chance of reaching an agreement between the United States and Iran", Al Hadath reports

Iranian Security Council Secretary Rezaei says a new escalation from the US could open a 2nd front alongside the Strait of Hormuz, in Bab El-Mandeb